Leerink Partnrs Weighs in on Tourmaline Bio Q3 Earnings

Tourmaline Bio, Inc. (NASDAQ:TRML) – Equities researchers at Leerink Partnrs raised their Q3 2025 earnings per share (EPS) estimates for Tourmaline Bio in a report released on Wednesday, August 13th. Leerink Partnrs analyst T. Smith now forecasts that the company will post earnings of ($0.96) per share for the quarter, up from their prior forecast of ($1.00). The consensus estimate for Tourmaline Bio’s current full-year earnings is ($3.02) per share. Leerink Partnrs also issued estimates for Tourmaline Bio’s FY2025 earnings at ($3.61) EPS, FY2026 earnings at ($4.33) EPS, FY2027 earnings at ($5.52) EPS, FY2028 earnings at ($7.33) EPS and FY2029 earnings at ($4.51) EPS.

Several other equities research analysts have also recently issued reports on the company. HC Wainwright reiterated a “buy” rating and issued a $50.00 price target on shares of Tourmaline Bio in a research note on Monday, May 5th. Guggenheim reiterated a “buy” rating and issued a $55.00 price target on shares of Tourmaline Bio in a research note on Thursday, August 14th. Finally, Chardan Capital reiterated a “buy” rating and issued a $70.00 price target on shares of Tourmaline Bio in a research note on Thursday, August 14th. Seven analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $50.14.

Tourmaline Bio Stock Up 0.9%

Shares of NASDAQ:TRML opened at $22.37 on Monday. Tourmaline Bio has a 12-month low of $11.56 and a 12-month high of $29.79. The stock has a market cap of $574.46 million, a PE ratio of -6.52 and a beta of 2.04. The business has a 50 day moving average of $19.18 and a 200-day moving average of $16.65.

Tourmaline Bio (NASDAQ:TRML) last issued its quarterly earnings data on Wednesday, August 13th. The company reported ($0.90) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.94) by $0.04.

Institutional Investors Weigh In On Tourmaline Bio

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC lifted its stake in Tourmaline Bio by 297.6% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,646 shares of the company’s stock worth $33,000 after purchasing an additional 1,232 shares during the last quarter. BNP Paribas Financial Markets lifted its stake in Tourmaline Bio by 34.1% during the second quarter. BNP Paribas Financial Markets now owns 2,103 shares of the company’s stock worth $34,000 after purchasing an additional 535 shares during the last quarter. Tower Research Capital LLC TRC lifted its stake in Tourmaline Bio by 35.7% during the second quarter. Tower Research Capital LLC TRC now owns 3,214 shares of the company’s stock worth $51,000 after purchasing an additional 846 shares during the last quarter. Brooklyn Investment Group lifted its stake in Tourmaline Bio by 148.9% during the first quarter. Brooklyn Investment Group now owns 3,923 shares of the company’s stock worth $60,000 after purchasing an additional 2,347 shares during the last quarter. Finally, Virtus ETF Advisers LLC bought a new stake in Tourmaline Bio during the fourth quarter worth $64,000. 91.89% of the stock is currently owned by institutional investors.

Tourmaline Bio Company Profile

Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.